Navigation Links
Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
Date:2/12/2009

ilable treatments for rosacea, primarily oral and topical antibiotics, which involve long-term tolerability and other health concerns. Pyratine-XR(TM) produced a progressive decrease in the symptoms associated with rosacea including redness and lesions. All subject self-assessments showed good tolerability and cosmetic acceptability.

After 48 weeks, there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. The investigators saw continual, statistically significant mean improvement with Pyratine-XR(TM) treatment, including a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The product was well tolerated, and in an earlier assessment of 24 patients, there was a 41% mean improvement in skin dryness as early as week four, with results continuing to improve over the 48- week period. Pyratine-XR(TM) produced a significant improvement in skin barrier function at weeks 4 through 48 as measured by a decrease in water loss from the skin.

"We are incredibly pleased with the results reported in this rosacea- specific study, with continual improvement in lesions, redness and spider veins. Unlike current therapies, Pyratine-XR(TM) was well tolerated by all patients, and offers hope to a myriad of individuals suffering from facial redness, acne lesions and spider veins, such as those afflicted with eczema, atopic dermatitis and rosacea. We are pleased that the study results are being presented by Dr. Nestor at this prestigious meeting," said Frank J. Massino, Chairman and CEO of Senetek PLC. "The clinical trials are extremely promising, and we anticipate a tremendous physician and patient response to Pyratine- XR(TM), which will officially launch at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009."

About Senetek, PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a l
'/>"/>

SOURCE Senetek, PLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
2. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
5. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
6. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
7. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
8. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
9. Micromet Expands Committed Equity Financing Facility to $75 Million
10. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Partnership to accelerate Trudeau Institute discoveries to patient care 8711 1Partnership to accelerate Trudeau Institute discoveries to patient care 8711 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 1Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 3WWII Veterans Compete in National Veterans Golden Age Games 47813 1WWII Veterans Compete in National Veterans Golden Age Games 47813 2
...NTA, Dec. 11 The Arthritis Foundation,the leading...llion,Americans living with arthritis, today annou...eters of Enbrel (R) (etanercept), will be the,nati... (R)., "The Arthritis Foundation hosts hundreds o...to prevent, control and cure arthritis, the,nation...
...CETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNe...(NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ...ze ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 ... for the treatment of virologically suppressed adu... approval by the European,Commission. If approved,...
Other Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, CHICA...nited States House of Representatives passed by a ...lation that would strengthen Medicare for seniors ... prices millions of Americans out of affordable he...
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, BALTI... Tonight the United States House of Representative...hat would strengthen Medicare for seniors and end ...millions of Americans out of affordable health cov...
(Date:11/7/2009)...ON, Nov. 7 Karen Ignagn... Plans (AHIP), released the following statement to...lans strongly support comprehensive health care re...y proposing a complete overhaul of how health insu...guaranteed coverage, elimination of pre-existing c...
(Date:11/7/2009)... Nov. 7, The American M...njamin Rush Award for Citizenship and Community Se...from Chicago, IL. The award recognizes physicians ...call of duty to make an outstanding public service...received the award today during the opening sessio...
(Date:11/7/2009)...yn T. Coleman (CT), David A. Cook (GA), Louis J. G... (LA) Honored ,, CHICAGO, Nov. 7 /PRNewswire-U...A) today presented five medical society executive ...tributions to the goals and ideals of the medical ... semi-annual policy making meeting in Houston. ,...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2
...he Prescription Drug User Fee Act (PDUFA) user fee...ry 18, 2008 -, YARDLEY, Pa., Sept. 20 Tibotec Ph...ug Application (NDA) for TMC125,(etravirine), an i...stration (FDA). The Prescription Drug User Fee,Act...
...LIN, N.J., Sept. 20 SyntheMed, Inc. (OTC,Bulletin...he development,and commercialization of anti-adhes...t the Circulatory System Devices Advisory Panel of...,likely to need secondary open heart surgery. The ...
...phyX(TM) receives FDA clearance, REDMOND, Wash., ... EsophyX(TM) device for performing Transoral Incis...ing gastroesophageal reflux,disease has received F...pleted yesterday under general anesthesia,transora...
...BOSTON Since the days of Hippocrates, people have ...seasons. More recently, researchers have learned t...seasonality, are often related to the weather. In ... Department of Public Heath and Family Medicine at...
...(Washington) Expressions of deep concern and disa...authorization will go forward without addressing s...for Medicare beneficiaries were sent today to cong...nal medicine physicians and medical student member...
...ndation Duped By Overseas Supplier, WAKEFIELD, Ma...tion established to support cancer-fighting resear...ng due to high lead levels the jewelry it,distribu... contain lead. When Friends of Mel recently learne...
Other Medicine News:Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 2Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 3Health News:FDA Panel Recommends Approval of SyntheMed's REPEL-CV(R) Adhesion Barrier for Pediatric Patients 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 3Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 4Health News:Mathematics might save you a trip to the ER 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 2Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 3
Assay Development
Custom Conjugation
Iso-Electric Determination Kit
Rabbit Anti-Goat IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD
Medicine Products: